NR ARUC
AU van Everbroeck,B.R.J.; Boons,J.; Cras,P.
TI 14-3-3 gamma-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias
QU Journal of Neurology, Neurosurgery and Psychiatry 2005 Jan; 76(1): 100-2
PT evaluation studies; journal article
AB We developed a polyclonal antiserum directed to the gamma-isoform of the human 14-3-3 protein and compared the immunoreactivity with a commercially available antibody (CG31). We analysed 14-3-3 in 253 cerebrospinal fluid samples blinded for the diagnosis by western blot and ELISA, with a commonly used polyclonal antiserum (Sc-731) and the gamma specific antibodies. Our patient population consisted of 52 patients with definite sporadic Creutzfeldt-Jakob disease (sCJD) and 201 patients with a different final diagnosis. We obtained similar sensitivity, ranging from 96% to 98% with all antibodies. Of all the samples that were false positive with Sc-731, 50% were negative with both gamma-isoform specific antibodies resulting in a significantly higher specificity (85% v 93%, respectively). If only sCJD and patients with dementia differing from sCJD were analysed we found that 64% of false positives were negative which also resulted in significantly increased specificity and positive predictive value.The gamma-isoform specific antibodies strongly improve the specificity of the immunoblot and might improve worldwide acceptance of the use of the 14-3-3 assay in the differential diagnosis of sCJD.
MH 14-3-3 Proteins/*cerebrospinal fluid; Blotting, Western; Creutzfeldt-Jakob Syndrome/cerebrospinal fluid/*diagnosis; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Humans; Research Support, Non-U.S. Gov't; Sensitivity and Specificity
AD Laboratory of Neurobiology, Born Bunge Foundation (BBS), University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Wilrijk, Belgium. bart.vaneverbroeck@ua.ac.be
SP englisch
PO England